IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings

Benzinga2021-06-15

This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.

AMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.

Molecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.

WalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.

WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.

Convey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.

Angel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.

Lyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.

GlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.

Verve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.

Atai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.

The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.

AiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.

The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Vincentoh
2021-06-18
Vincentoh
[財迷] [財迷]
Vincentoh
2021-06-18
Vincentoh
[財迷] [財迷]
Vincentoh
2021-06-18
Vincentoh
[財迷] [財迷]
Nonemu
2021-06-17
Nonemu
Anyone like $AiHuiShou International Co. Ltd.(RERE)$
JoelSeah
2021-06-16
JoelSeah
Go for AOMR
Meshaarias72
2021-06-15
Meshaarias72
?

Leave a comment

171

205

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175897310?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-15 10:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175897310","market":"us","top_or_hot":-1,"title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","media":"Benzinga","content":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n2021-06-15 10:51 北京时间&nbsp;&nbsp;&nbsp;Benzinga\n\n</h4>\n\n</header>\n<article>\n<div>\nThis week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:...\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":null,"article_id":"1175897310","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","pubTimestamp":1623725513,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华","WKME":"WalkMe Ltd.","ATAI":"ATAI Life Sciences B.V.*","RERE":"万物新生","LYEL":"Lyell Immunopharma, Inc.","AOMR":"ANGEL OAK MORTGAGE REIT INC","HKD":"尚乘数科","MOLN":"Molecular Partners AG"},"translate_title":"IPO预览：WalkMe和Atai生命科学将在一周内推出多只股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AOMR":0.9,"ATAI":0.9,"CNVY":0.9,"HKD":0.9,"LYEL":0.9,"MOLN":0.9,"NVS":0.9,"RERE":0.9,"WKME":0.9},"content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":168926952,"gmtCreate":1623947427476,"gmtModify":1703824454038,"author":{"id":"3562140454798333","authorId":"3562140454798333","name":"Vincentoh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562140454798333","authorIdStr":"3562140454798333"},"htmlText":"[財迷]&nbsp;[財迷]&nbsp;","listText":"[財迷]&nbsp;[財迷]&nbsp;","text":"[財迷] [財迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168926952","repostId":1175897310,"repostType":2,"repost":{"id":"1175897310","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://ttm.financial/m/news/1175897310?lang=&edition=fundamental","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nBenzinga \n2021-06-15 10:51\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\nThis week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MOLN":"Molecular Partners AG","HKD":"尚乘数科","AOMR":"ANGEL OAK MORTGAGE REIT INC","WKME":"WalkMe Ltd.","ATAI":"ATAI Life Sciences B.V.*","RERE":"万物新生","LYEL":"Lyell Immunopharma, Inc.","NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":168928255,"gmtCreate":1623947416377,"gmtModify":1703824453710,"author":{"id":"3562140454798333","authorId":"3562140454798333","name":"Vincentoh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562140454798333","authorIdStr":"3562140454798333"},"htmlText":"[財迷]&nbsp;[財迷]&nbsp;","listText":"[財迷]&nbsp;[財迷]&nbsp;","text":"[財迷] [財迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168928255","repostId":1175897310,"repostType":2,"repost":{"id":"1175897310","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://ttm.financial/m/news/1175897310?lang=&edition=fundamental","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nBenzinga \n2021-06-15 10:51\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\nThis week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MOLN":"Molecular Partners AG","HKD":"尚乘数科","AOMR":"ANGEL OAK MORTGAGE REIT INC","WKME":"WalkMe Ltd.","ATAI":"ATAI Life Sciences B.V.*","RERE":"万物新生","LYEL":"Lyell Immunopharma, Inc.","NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":168921326,"gmtCreate":1623947382365,"gmtModify":1703824451568,"author":{"id":"3562140454798333","authorId":"3562140454798333","name":"Vincentoh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562140454798333","authorIdStr":"3562140454798333"},"htmlText":"[財迷]&nbsp;[財迷]&nbsp;","listText":"[財迷]&nbsp;[財迷]&nbsp;","text":"[財迷] [財迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168921326","repostId":1175897310,"repostType":2,"repost":{"id":"1175897310","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://ttm.financial/m/news/1175897310?lang=&edition=fundamental","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nBenzinga \n2021-06-15 10:51\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\nThis week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MOLN":"Molecular Partners AG","HKD":"尚乘数科","AOMR":"ANGEL OAK MORTGAGE REIT INC","WKME":"WalkMe Ltd.","ATAI":"ATAI Life Sciences B.V.*","RERE":"万物新生","LYEL":"Lyell Immunopharma, Inc.","NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":161828339,"gmtCreate":1623918786521,"gmtModify":1703823472906,"author":{"id":"3574462598365139","authorId":"3574462598365139","name":"Nonemu","avatar":"https://static.tigerbbs.com/2b2aa796d762f47f807c009aff8c3cd3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574462598365139","authorIdStr":"3574462598365139"},"htmlText":"Anyone like&nbsp;<a href=\"https://laohu8.com/S/RERE\">$AiHuiShou International Co. Ltd.(RERE)$</a>","listText":"Anyone like&nbsp;<a href=\"https://laohu8.com/S/RERE\">$AiHuiShou International Co. Ltd.(RERE)$</a>","text":"Anyone like $AiHuiShou International Co. Ltd.(RERE)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/161828339","repostId":1175897310,"repostType":2,"repost":{"id":"1175897310","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://ttm.financial/m/news/1175897310?lang=&edition=fundamental","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nBenzinga \n2021-06-15 10:51\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\nThis week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MOLN":"Molecular Partners AG","HKD":"尚乘数科","AOMR":"ANGEL OAK MORTGAGE REIT INC","WKME":"WalkMe Ltd.","ATAI":"ATAI Life Sciences B.V.*","RERE":"万物新生","LYEL":"Lyell Immunopharma, Inc.","NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":169647338,"gmtCreate":1623835087524,"gmtModify":1703820879138,"author":{"id":"3585452666972742","authorId":"3585452666972742","name":"JoelSeah","avatar":"https://static.tigerbbs.com/7209ed7c109a0f0d11e650747fe83336","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3585452666972742","authorIdStr":"3585452666972742"},"htmlText":"Go for AOMR","listText":"Go for AOMR","text":"Go for AOMR","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/169647338","repostId":1175897310,"repostType":2,"repost":{"id":"1175897310","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://ttm.financial/m/news/1175897310?lang=&edition=fundamental","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nBenzinga \n2021-06-15 10:51\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\nThis week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MOLN":"Molecular Partners AG","HKD":"尚乘数科","AOMR":"ANGEL OAK MORTGAGE REIT INC","WKME":"WalkMe Ltd.","ATAI":"ATAI Life Sciences B.V.*","RERE":"万物新生","LYEL":"Lyell Immunopharma, Inc.","NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187794357,"gmtCreate":1623764050679,"gmtModify":1703818586365,"author":{"id":"3577781617271173","authorId":"3577781617271173","name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577781617271173","authorIdStr":"3577781617271173"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187794357","repostId":1175897310,"repostType":4,"repost":{"id":"1175897310","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://ttm.financial/m/news/1175897310?lang=&edition=fundamental","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nBenzinga \n2021-06-15 10:51\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\nThis week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform&nbsp;AMTD Digital(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company&nbsp;Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and&nbsp;AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company&nbsp;Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company&nbsp;Angel Oak Mortgage(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and&nbsp;Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby&nbsp;Palantir Technologies(NYSE:PLTR) and&nbsp;Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller&nbsp;AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MOLN":"Molecular Partners AG","HKD":"尚乘数科","AOMR":"ANGEL OAK MORTGAGE REIT INC","WKME":"WalkMe Ltd.","ATAI":"ATAI Life Sciences B.V.*","RERE":"万物新生","LYEL":"Lyell Immunopharma, Inc.","NVS":"诺华"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":205,"commentSize":171,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175897310"}